WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--April 20, 2006--Endocyte Inc., today announced the initiation of a Phase 1 clinical trial with EC145, a folate-targeted cytotoxic anti-cancer drug. The open-label, non-randomized, dose escalation study is designed to evaluate the safety and tolerability of EC145 and to identify the dose to be used in future Phase 2 efficacy trials.
